TBK1 and neoplasm: This was shown by Jenkins et al. [122] analyzing mouse-derived and patient-derived organotypic tumor spheroids including autologous immune and stroma cells to analyze the effects of a combined immune checkpoint blockade with PD-1 and TANK-binding kinase 1/I-kappa-B kinase epsilon (TBK1/IKKε) inhibitors, so-called compound 1 (Cmpd1).